Mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH) is an essential component of the glycerol phosphate shuttle that transfers reduction equivalents from the cytosol into the mitochondrion. Within the testis, immunohistological analysis localized human mG-PDH to late spermatids and to the midpiece of spermatozoa. The expression of human mGPDH is regulated by two somatic promoters, and here, we describe a third testis-specific promoter of human mGPDH. The usage of this testis-specific promoter correlates with the expression of a shortened mGPDH transcript of ϳ2.4 kb in length, which is solely detectable from testicular RNA. Within the testis-specific promoter, we detected a cAMPresponse element (CRE) site at ؊51, which binds the testis-specific transcriptional activator CRE modulator (CREM) in electrophoretic mobility shift assays. This recognition site overlaps with a nuclear receptor binding half-site at ؊49, which binds the testis-specific transcriptional repressor germ cell nuclear factor (GCNF). Both factors compete for binding to the same DNA response element. Ectopic expression of CREM in HepG2 cells activated a promoter-driven luciferase construct in transient transfection experiments. Additional cotransfection of GCNF relieved this activity, suggesting a down-regulation of CREM-mediated activation by GCNF. This effect was preserved by introducing the CRE/nuclear receptor-binding element into a heterologous promoter context. Our data suggest a down-regulation of CREM-mediated gene expression by GCNF, which might be a general regulation mechanism for several postmeiotically expressed genes with a temporal expression peak during early spermatid development.
Mitochondrial glycerol-3-phosphate dehydrogenase (mG-PDH) 1 is an essential component of the glycerol phosphate shuttle. In conjunction with the cytosolic glycerol-3-phosphate dehydrogenase, this shuttle uses the interconversion of glycerol-3-phosphate to dihydroxyacetone phosphate to oxidize cytosolic NADH by transferring reduction equivalents from the cytosol to the mitochondrion (1, 2) . The expression of human and rat mGPDH is regulated by two somatic promoters in a tissue-specific manner (3) (4) (5) (6) (7) , but rat mGPDH is additionally regulated by a third testis-specific promoter (8) . The usage of the testis-specific promoter of mGPDH results in a shortened transcript length of ϳ2.4 kb containing an alternate first exon at its 5Ј end and a shortened 3Ј-untranslated region; however, the open reading frame remains unaffected (3, 8) . In rat testis, mGPDH transcripts have been detected in postmeiotic germ cells during early spermatid development, whereas mGPDH proteins have been detected during late spermatid development (8) . The knockout of mGPDH in transgenic mice leads to reduced fertility (9, 10) . Within the testis, spermatogenesis is a complex developmental process that includes the mitotic proliferation of spermatogonial stem cells, meiotic prophase, division of spermatocytes, and morphological changes of haploid spermatids to highly specialized spermatozoa (reviewed in Ref. 11) . The developmental program of spermatogenesis is regulated by several testis-specific transcription factors, e.g. the cAMP-response element modulator (CREM) or the germ cell nuclear factor (GCNF).
CREM, a testis-specific transcriptional activator, is an alternative splice product of the CREM gene belonging to a family of proteins, which are regulated by cAMP and bind to cAMP DNA-response elements (CREs) (consensus sequence: 5Ј-TGACGTCA-3Ј) (12, 13) . Target gene disruption of the CREM gene (including CREM) leads to infertility in transgenic mice (14, 15) . Moreover, CRE-binding sites have frequently been observed in testicular expressed genes implicated in spermatogenesis and fertility (8, 16, 17) , suggesting a critical role for CREM in proper regulation of these genes during spermatogenesis.
Germ cell nuclear factor (also known as retinoid receptorrelated testis-associated receptor) is a member of the nuclear receptor superfamily of ligand-activated transcription factors (18, 19) ; however, a ligand for GCNF is currently unknown. Target gene disruption of GCNF leads to embryonic lethality (20) . In vitro studies suggested that GCNF acts as a transcriptional repressor and may inhibit transcriptional activation mediated by other nuclear receptors (21, 22) . GCNF can specifically bind to direct repeats of nuclear receptor half-site (5Ј-AGGTCA-3Ј) with zero base pair spacing between the half-sites or to extended single half-sites (23, 24) . The binding sites for GCNF have been described e.g. within the protamine gene promoters that are expressed from postmeiotic male germ cells (16, 23, 25) .
In this study, we reported the identification and initial characterization of a testis-specific promoter of human mGPDH. mGPDH contributes to the aerobic metabolism of sperms powering its motility, which is required for fertilization. The testicular expression of mGPDH is regulated by a balanced activity between CREM and GCNF, which might be a general regulation mechanism for several postmeiotically expressed target genes implicated in sperm motility and fertility.
EXPERIMENTAL PROCEDURES
Isolation and Characterization of DNA Sequences-A human promoter C fragment was amplified by PCR using primers hum1 (5Ј-AC-TGTGTTGTATATAACTTCC-3Ј) and hum2 (5Ј-GAAGACAGAGAATA-AAGTCC-3Ј) and human genomic DNA as template. The resulting 211-bp PCR fragments (corresponding to nucleotide positions 101880 -102090; GenBank TM accession number AC092686) were gel-purified, ligated into pGEM-T Easy (Promega, Mannheim, Germany), and sequenced. This promoter fragment was further subcloned into pGL3-Basic (Promega) upstream of the luciferase gene, generating the construct hu(Ϫ106/ϩ105)-Luc.
Human promoter C sequence from Ϫ57 to Ϫ38 (5Ј-CCTTTGTGAG-GTCATGAATG-3Ј, see Fig. 1 ) was designed as double-stranded oligonucleotides and ligated upstream of the minimal rat prolactin promoter (from Ϫ38 to ϩ36) into pGL3-Basic (26) , generating the construct CREwt-rPRL-Luc. A mutant variant of this construct was similarly designed using oligonucleotides containing the sequence 5Ј-CCTTT-GTCTGGAGATGAATG-3Ј (the italic residues indicated the mutated one compared with wild type), resulting in the construct CREmut-rPRL-Luc.
To characterize the 5Ј end of human testicular mGPDH mRNA, we used a rapid amplification of cDNA ends (RACE) technique, which allows only amplification from full-length transcripts with an intact 5Ј-cap structure (GeneRacer, Invitrogen) as described previously (8) . RNA was isolated from testis tissue of two patients aged older than 50 years who were undergoing orchiectomy as the primary treatment of prostatic carcinoma. RNA was reverse-transcribed with the mGPDHspecific primer WL274 (5Ј-CAGATATCTCACACCACCATGG-3Ј). The 5Ј end amplification was performed with the GeneRacer 5Ј primer and the mGPDH-specific primer WL273 (5Ј-TGAGCTTCTCTGGAAGGAG-G-3Ј) using the PCR setup and cycling parameters suggested by the supplier's protocol. These first amplification products were subjected to a nested PCR using GeneRacer 5Ј-nested primer and the gene-specific nested primer WL301 (5Ј-ACAGTTGCAAGAGCACCTCC-3Ј). The amplification products were gel-purified, ligated into pGEM-T Easy, and sequenced.
mRNA Expression Analysis-Multiple human tissue Northern blots were obtained from Clontech (Heidelberg, Germany). A human mGPDH cDNA probe was prepared with [␣-32 P]dCTP by random prime labeling (Roche Applied Science). Prehybridization, hybridization, and washing were performed under high stringency conditions according to the manufacturer's instructions. To control for the relative amount of RNA in each lane, after hybridization with mGPDH cDNA, the blots were stripped by boiling in 0.1% SDS for 1 min and reprobed with a human glyceraldehyde-3-phosphate dehydrogenase cDNA.
Quantitative "real-time" PCR was conducted using the LC-DNA Master SYBR Green kit in a LightCycler (Roche Applied Science) as described previously (27) . Testicular RNA was prepared as described above and reverse-transcribed with a mixture of random hexamer and oligo(dT) primers (Amersham Biosciences). Exon 1-specific PCR reactions (4) were performed using the common human mGPDH-specific reverse primer WL273 and the following human exon 1-specific forward primers: exon 1a, WL285 (5Ј-GAGTAGGAGAAGCCAGATCC-3Ј); exon 1b, WL304 (5Ј-GCCGAGGCTCTGATTCTGG-3Ј); and exon 1c, WL192 (5Ј-ATCAGTCACAACACTCATATCC-3Ј). Rat mGPDH-specific primers were as described previously (4). The crossing points of target gene amplification products were normalized to the crossing points of the "housekeeping" gene ubiquitin using the standard adjustments recommended by the supplier as described previously (27) .
Electrophoretic Mobility Shift Assay-In vitro translated CREM, C-terminally fused with the FLAG epitope (26) , and GCNF, N-terminally fused with the hemagglutinin (HA) epitope (28) , were synthesized by a transcription/translation-coupled reticulocyte lysate system (Promega) according to the manufacturer's instructions. 1 l of in vitro translated CREM or GCNF was incubated with 10 fmol of radioactively labeled double-stranded oligonucleotide probe hu(Ϫ62/Ϫ32) (5Ј-GGTATCCTTTGTGAGGTCAACAATGACATTA-3Ј) in the presence of 1 g of poly(dA-dT)⅐poly(dA-dT) as described previously (8) . For competition experiments, a 100-fold molar excess of double-stranded oligonucleotides wild-type hu(Ϫ62/Ϫ32), mutated hu(Ϫ62/Ϫ32) (5Ј-GGTATC-CTTTGTCTGGAGAACAATGACATTA-3Ј) (the italic residues indicated the mutated one compared with wild type), or wild-type hu(Ϫ106/ϩ105) was added to the binding reaction. For supershift experiments, 1 l of rabbit polyclonal anti-CREM (Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal anti-HA (Cell Signaling Technology, Frankfurt am Main, Germany), or mouse monoclonal anti-FLAG (M2) (Sigma) antibodies were added to the binding reaction mixtures and preincubated for 30 or 60 min at room temperature. The shifted DNA bands were separated on 5% polyacrylamide gels and visualized by autoradiography on Kodak X-Omat AR films (Eastman Kodak Co.).
Transient Transfection Assay-Human hepatocarcinoma HepG2 cells were cultured under standard conditions in Dulbecco's modified Eagle's medium plus Glutamax (Invitrogen) and 10% fetal calf serum as described previously (4, 7). Transient transfection experiments were performed using a modified calcium phosphate technique. For each 9.6-cm 2 dish, 1.4 g of the promoter containing pGL3-Basic luciferase reporter plasmid (for constructs, see above) was mixed with 0.8 g of CREM and 0.8, 1.6, or 2.4 g of GCNF expression plasmids or the corresponding amount of unspecific salmon sperm DNA in 250 mM CaCl 2 . This solution was mixed with the same volume of 280 mM NaCl, 3 mM Na 2 HPO 4 , and 50 mM HEPES, pH 7.2, and incubated for 30 min. 230 l of the DNA/calcium phosphate mixture was added drop by drop to the culture medium containing ϳ7 ϫ 10 5 cells/well, and the cells were harvested after an 18-h incubation. Expression plasmids were as follows: CREM; CREM-10/FLAG and CREM␣; CREM-22/FLAG in pRc/ cytomegalovirus (all gifts of Birgit Gellersen) (26); and GCNF in pCMX (a gift of Uwe Borgmeyer) (24) . Luciferase activities were determined as described previously (4, 7) and normalized to the total protein concentration of the samples, which were determined by the Bradford method (Bio-Rad). Luciferase assays were carried out in duplicate, and each construct was tested in at least five independent transfections with three culture dishes/experiment Ϯ S.D. Significant values were estimated by Student's t test.
Immunohistochemistry-Immunohistochemistry experiments of human testis tissue using an anti-mGPDH-specific antibody (directed against amino acids 42-206 of mGPDH) were performed as described previously (8) . Partial testes tissues were obtained from fertile patients aged from 20 to 40 years with intact spermatogenesis who were investigated to exclude a testicular tumor. For immunohistological analysis of mGPDH in spermatozoa, sperm suspensions were centrifuged (649 ϫ g, 1 min), the supernatant was discarded, and the pellet was fixed by the administration of 4% paraformaldehyde in phosphate-buffered saline (PBS) (136 mM NaCl, 50 mM Na 2 HPO 4 , pH 7.4) followed by application to BD Falcon culture slides. After sedimentation (40 min, 4°C), the supernatant was discarded and chambers were washed with PBS followed by drying of spermatozoa at 36°C to improve adhesion. Subsequently, chambers were washed with PBS again and incubated with 2% normal swine serum (DAKO, Hamburg, Germany) in PBS containing 0.5% Triton X-100 for 30 min. Normal swine serum was replaced by primary antibody solution (0.2% bovine serum albumin, 0.1% NaN 3 , 0.5% Triton X-100 in PBS) containing rabbit polyclonal anti-mGPDH (1:600). Spermatozoa were incubated with the primary antibody at 4°C overnight followed by three washing cycles with PBS. Secondary antibody (anti-rabbit IgG (Alexa 488 nm) (1:1000), Molecular Probes, Lexington, KY) was administered in PBS containing 0.5% Triton X-100 for 60 min in a dark chamber. Slides were washed with PBS three times and covered for fluorescence microscopy (Zeiss Axioskop, filter set 09, Zeiss, Oberkochen, Germany). For negative controls, the primary antibody was omitted or preimmune serum (1:600) was used instead of the antibody.
RESULTS

Identification of Human mGPDH
Promoter C-To test the hypothesis that human mGPDH might be regulated by a testisspecific promoter, we performed a BLAST search using the rat promoter C sequence (GenBank TM accession number AJ495842) as query sequence against the entire GenBank TM data base entries. We were able to detect a human sequence with a sequence identity of 87% (see Fig. 1 ). A detailed inspection located this sequence 36.9 kb downstream of exon 1b and 2.3 kb upstream of exon 2 within the human mGPDH gene on chromosome 2q24.1 (GenBank TM accession number AC092686), suggesting a human orthologous sequence of promoter C.
The usage of promoter C in rat correlates with an alternative transcript variant, which contains the sequence of the nontranslated exon 1c at its 5Ј end (3, 4 
FIG. 2.
A, expression analyses of mG-PDH in 23 human tissues. Multiple tissue Northern blots were hybridized using radioactively labeled probes from mGPDH and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), respectively. Transcript lengths are indicated in kb. B, relative abundance of exon 1-containing mGPDH transcripts in human and rat testicular RNA. Human and rat testicular RNA were reverse-transcribed and adjusted to a quantitative real-time PCR amplification using different exon 1-specific forward and common reverse primers. Expression levels of exon 1c-containing transcripts (1c) were normalized to the expression levels of exon 1b-containing transcripts (1b). cules, which have been generated from full-length transcripts (see "Experimental Procedures"), we simultaneously mapped the major transcriptional start site (Fig. 1, designated as ϩ1 , boldface arrow) and identified four additional alternate start sites (Fig. 1, fine arrows) of these transcripts.
Northern blot analysis from rodent RNA detected a short mGPDH transcript of ϳ2.4 kb solely in testis, whereas most somatic tissues contain a longer transcript of ϳ6.5 kb (3, 29, 30) . To test whether this testis-specific transcript might also be detectable from human tissues, we performed Northern blot analysis from 23 human tissue samples. As shown in Fig. 2A , a short transcript of ϳ2.4 kb was solely detectable from testicular RNA. For quantification of the concentration of exon 1b-and exon 1c-containing transcripts in human and rat testes, we conducted a quantitative real-time PCR assay. As shown in Fig. 2B , exon 1c-containing transcripts were 2.6-fold as much expressed as exon 1b-containing transcripts in human, whereas exon 1c-containing transcripts were 23-fold higher expressed than exon 1b-containing transcripts in rat. This correlates well with the ratio of 6.5 to 2.4 kb transcript in human ( Fig. 2A) , rat, and mouse testes (3, 29) and may also correlate with the different spermatogenesis efficiencies in rodents and man.
Transient Transfection Experiments-To examine the regulation of human mGPDH promoter C in testis, we introduced a sequence of the promoter from Ϫ106 to ϩ105 into a luciferase reporter construct (hu(Ϫ106/ϩ105)-luc). This sequence portion includes the highly conserved region between rat and human ( Fig. 1) and has previously been identified to be the important sequence for promoter C activity in rat (8) . After transfection of the construct hu(Ϫ106/ϩ105)-luc into HepG2 cells, the promoter activity was barely detectable. In contrast, additional cotransfection of the transcriptional activator CREM increased the hu(Ϫ106/ϩ105)-Luc activity 9-fold above background level (Fig. 3A) . This activation was completely blocked after additional cotransfection with increasing amounts of the transcriptional repressor GCNF (Fig. 3A) .
Because sequence inspections identified a putative CRE site from Ϫ51 to Ϫ44 (Fig. 1) , we introduced a sequence portion from Ϫ57 to Ϫ38 into a reporter plasmid upstream of the minimal rat prolactin promoter, generating the heterologous promoter construct CREwt-rPRL-Luc. As shown in Fig. 3B , the induction of CREwt-rPRL-Luc after cotransfection of CREM into HepG2 cells was well preserved within this region. Cotransfection of CREM␣ (lacking the activator domain of CREM) had no significant influence on the promoter activity. Furthermore, the activation of CREM depended on the presence of an intact CRE site because mutation of this site (CREmut-rPRL-Luc) prevented activation (Fig. 3B) .
The CRE site contains the sequence 5Ј-TGAGGTCA-3Ј (Fig.  1, Ϫ51/Ϫ44 ), thus differing from the sequence of a typical CRE site (5Ј-TGACGTCA-3Ј) by one nucleotide. Interestingly, this nucleotide exchange generates a putative nuclear receptor (NR)-binding half-site 5Ј-AGGTCA-3Ј (Fig. 1, Ϫ49/Ϫ44 ). To test that this site might be a functional binding site for nuclear receptors, we cotransfected the testis-specific transcriptional repressor GCNF together with the reporter construct CREwtrPRL-Luc and CREM into HepG2 cells. As shown in Fig. 3B , GCNF was able to relieve the CREM-mediated activation of CREwt-rPRL-Luc, suggesting an interference of CREM and GCNF signal pathways.
Electrophoretic Mobility Shift Assay-We next tested whether an in vitro translated FLAG-tagged CREM is able to bind to the CRE/NR site. Incubation of CREM with a radioactively labeled DNA fragment containing the CRE/NR site (Ϫ62/Ϫ32) generated slower migrating bands in electrophoretic mobility shift assay experiments (Fig. 4A, arrows) . These CREM⅐DNA complexes were abolished by the addition of a 100-fold molar excess of unlabeled wild-type CRE/NR fragment but not by the addition of a 100-fold molar excess of unlabeled mutated CRE/NR site-containing fragment. Incubation with an anti-CREM antibody abolished the formation of the CREM⅐DNA complexes, whereas an anti-FLAG antibody supershifted this complex to lower mobility (Fig. 4A, arrowhead) .
To evaluate that this DNA element is also able to bind to the nuclear receptor GCNF, we incubated the same CRE/NR sitecontaining DNA fragment (Ϫ62/Ϫ32) with an in vitro translated HA-tagged GCNF. As shown in Fig. 4B , GCNF binds to the CRE/NR site, which includes the putative nuclear receptor half-site (Fig. 4B, arrow) . The GCNF⅐DNA complex was abolished by the addition of a 100-fold molar excess of unlabeled CRE/NR wild-type fragment or an excess of fragment Ϫ106/ ϩ105 but not by addition of a 100-fold molar excess of CRE/ NR-mutated fragment, which simultaneously mutated the nuclear receptor half-site. After incubation with an anti-HA antibody, the GCNF⅐DNA complex was supershifted to lower mobility (Fig. 4B, arrowhead) . Thus, CREM and GCNF compete for binding to the same DNA element in which a CRE site overlaps with a NR-binding site.
Immunohistochemistry-To analyze the cellular localization of mGPDH within human testicular tissue, we incubated human testicular cross-sections with an anti-mGPDH-specific antibody. As shown in Fig. 5A , arrow, we observed an mGPDH immunostaining during spermatid differentiation of postmeiotic germ cells. Spermatid-specific staining was absent when preimmune serum was used instead of the antibody (Fig. 5B) .
To further investigate the localization of mGPDH within mature spermatozoa, we incubated spermatozoa with the antimGPDH antibody. As shown in Fig. 6, A and B , arrows, the midpiece of spermatozoa showed a strong immunoreactivity. Using the preimmune serum, the midpiece of spermatozoa remained unstained (Fig. 6, C and D, arrows) , whereas no immunostaining was observed by omitting the first antibody incubation (Fig. 6E) . The expression of these transcripts is regulated by promoter C, which is located upstream of exon 1c of the mGPDH gene (Fig.  1) . Second, the usage of promoter C in rat correlates with a shortened transcript length of ϳ2.4 kb (3, 29) . Among 23 human tissues, an mGPDH transcript of ϳ2.4 kb was solely detected from testis tissue, suggesting a very similar expression and splicing regulation in human testicular tissue ( Fig.  2A) . Third, an alignment of the rat promoter C sequence with human genomic sequences identified a 48-bp human sequence portion, which shows an 87% sequence identity (Fig. 1) . This sequence is located downstream of exon 1b and upstream of exon 2 sequences of the human mGPDH gene at roughly the same position compared with the rat orthologous mGPDH gene (3) .
The expression of mGPDH is high in those tissues with a high ATP turnover rate (3, 29) , suggesting an important role of mGPDH for appropriate energy production of these cells. Furthermore, human mGPDH was localized to late spermatids and to the mitochondria-rich midpiece of spermatozoa (Figs. 5 and 6) and, moreover, mGPDH knock-out mice showed a reduced fertility (10) . Thus, a tight regulation of the testis-specific promoter may responsible for proper fertility, both in man and mice. In this context, the dysfunction of mGPDH may result in reduced motility of spermatozoa and/or alterations of appropriate spermatid development. Further investigation of mGPDH knock-out mice should address these questions.
Regulation of the Testis-specific Promoter by CREM and GCNF-A sequence inspection of the testis-specific promoter of human mGPDH identified the sequence 5Ј-TGAGGTCA-3Ј at position Ϫ51 to Ϫ44 (Fig. 1) . This sequence differs from a typical CRE consensus sequence (5Ј-TGACGTCA-3Ј) by one nucleotide, thus generating a nuclear receptor-binding site (5Ј-AGGTCA-3Ј at Ϫ49 to Ϫ44). Interestingly, both the testisspecific transcriptional activator CREM (Fig. 4A) and the testis-specific transcriptional repressor GCNF (Fig. 4B) bind to this sequence motif in electrophoretic mobility shift assays.
Cell experiments demonstrated that CREM is able to activate a promoter C-containing reporter construct. This activation capacity is preserved within the CRE/NR motif as indicated by introducing this response element into a heterologous reporter construct. Moreover, the CREM-mediated activation is relieved after additional cotransfection of GCNF (Fig. 3, A  and B) .
Down-regulation of CREM-mediated Activation by GCNFInterestingly, the expression of rat mGPDH has been detected in postmeiotic germ cells restricted from round spermatid (step 2) up to early elongating spermatid (step 11) in a temporal expression peak (8) . Since CREM protein is highly detectable in round spermatids (31) , it may serve as a critical regulator for mGPDH up-regulation in round spermatids. GCNF expression reached maximal levels in stage VI-VIII spermatids (32, 33), and GCNF protein was detected at least until spermatids began to elongate (34, 35) . Therefore, it is tempting to speculate that CREM may be responsible for mGPDH up-regulation in round spermatids, whereas GCNF is responsible for down-regulation during elongating spermatid development. However, other regulation mechanisms such as posttranslational modifications (36) or competing for transcriptional cofactors (22, 37) may contribute to appropriate regulation of mGPDH.
Furthermore, an identical CRE/NR sequence motif, 5Ј-TGAGGTCA-3Ј, has also been described within the testis-specific promoter of the angiotensin-converting enzyme. This site has been located from Ϫ55 to Ϫ48 relative to the transcriptional start site and has been shown to be a binding site for CREM (17) . A small portion of the angiotensin-converting enzyme promoter from Ϫ91 to ϩ17 can efficiently target a reporter construct to step 4 -14 spermatids (38, 39) .
Thus, mGPDH and the testis-specific promoter of the angiotensin-converting enzyme have been shown to have the same critical response element and both proteins show similar temporal expression peaks during spermatid development. This expression pattern may be regulated by competing of the transcriptional activator CREM with the transcriptional repressor GCNF to the same binding site. Further investigations of CREM-and GCNF-regulated target genes should clarify whether this counteractive regulation might be a general regulation mechanism during spermatid development.
